13F Holdings
中文EN

ADMA ADMA BIOLOGICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1368514 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.3%
TTM net income YoY-12.9%
TTM EPS YoY-10.5%
Revenue 3-yr CAGR30.4%
Net income 3-yr CAGR—

Margins

Gross margin68.5%
Operating margin46.5%
Net margin35.1%
FCF margin25.6%
EBITDA margin47.9%

Returns

ROE41.9%
ROA28.0%
ROIC (approx.)39.4%
Asset turnover0.80x

Leverage & solvency

Liabilities / assets40.1%
Debt / equity0.45x
Current ratio6.04x
Interest coverage22.80x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio6.4%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$510.17M$426.45M$258.21M$154.08M$80.94M
Cost of revenue$217.41M$206.90M$169.27M$118.81M$79.77M
Gross profit$292.76M$219.55M$88.94M$35.27M$1.17M
R&D expense$4.76M$1.81M$3.30M$3.61M$3.65M
SG&A expense$91.58M$74.12M$59.02M$52.46M$42.90M
Operating income$191.44M$138.98M$21.63M-$39.37M-$58.37M
Interest expense$7.11M$13.93M$25.03M$19.28M$13.06M
Pretax income$182.66M$125.71M-$28.24M-$65.90M—
Income tax$35.73M-$71.96M$0$0$0
Net income$146.93M$197.67M-$28.24M-$65.90M-$71.65M
EBITDA$199.44M$146.68M$29.23M-$32.97M-$53.57M
EPS (basic)0.620.85-0.13-0.33-0.51
EPS (diluted)0.600.81-0.13-0.33-0.51
Weighted avg. shares (diluted)244.90M243.34M223.98M197.87M139.58M
Balance sheet
Cash & equivalents$87.63M$103.15M$51.35M$86.52M$51.09M
Receivables$158.43M$50.00M$27.42M$15.51M$28.58M
Inventory$206.47M$170.24M$172.91M$163.28M$124.72M
Current assets$466.51M$331.41M$257.01M$270.40M$208.73M
PP&E, net$65.06M$54.71M$53.84M$58.26M$50.94M
Goodwill$3.53M$3.53M$3.53M$3.53M$3.53M
Intangibles$632,000$460,000$499,000$1.01M$1.73M
Total assets$624.24M$488.68M$329.18M$348.46M$276.25M
Current liabilities$69.54M$55.54M$49.81M$39.27M$30.38M
Short-term debt$2.81M$0———
Long-term debt$69.33M$72.34M$130.59M$142.83M$94.87M
Total debt$72.14M$72.34M$130.59M$142.83M$94.87M
Total liabilities$146.92M$139.66M$193.98M$196.49M$135.08M
Shareholders' equity$477.32M$349.02M$135.21M$151.97M$141.17M
Net debt-$15.49M-$30.81M$79.24M$56.31M$43.78M
Shares outstanding237.87M236.62M226.06M221.82M195.81M
Cash flow statement
Operating cash flow$50.40M$118.67M$8.80M-$59.51M-$112.37M
Capital expenditure$22.57M$8.23M$4.77M$13.91M$13.51M
Free cash flow$27.82M$110.45M$4.03M-$73.42M-$125.88M
Investing cash flow-$21.89M-$8.57M-$4.98M-$13.91M-$13.51M
Financing cash flow-$44.02M-$58.30M-$38.99M$108.85M$121.05M
Depreciation & amortization$8.00M$7.70M$7.60M$6.40M$4.80M
Stock-based compensation$20.03M$13.62M$6.19M$5.21M$3.49M
Share buybacks$31.94M$0$0——

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.